Q-omics provides the consensus-scored MIR3199-1 profile across patient tissues and cancer cell-line models. MIR3199-1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR3199-1 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, MIR3199-1 RNA expression shows 5,656 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, CHOL, and STAD as cancer lineages where MIR3199-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3199-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3199-1 survival associations across molecular data types. MIR3199-1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3199-1 RNA expression–survival associations across cancer types. High MIR3199-1 expression shows unfavorable associations in UVM, ACC, MESO and THCA, but favorable associations in CESC and BRCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .035). Together, the overview and detailed table identify CESC as the clearest survival context for MIR3199-1 RNA expression.
This table summarizes MIR3199-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3199-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3199-1 shows higher tumor expression in CHOL, PRAD and BRCA. The CHOL box plot shows higher MIR3199-1 RNA expression in tumor versus normal tissue (log2 FC = +0.860, t-test p < 0.001).
This table shows molecular features associated with MIR3199-1 in patient tissues and cancer cell lines. In patient samples, MIR3199-1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
